| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Investigative Ophthalmology & Visual Science, Vol 37, 2485-2494, Copyright © 1996 by Association for Research in Vision and Ophthalmology
ARTICLES AND REPORTS |
MR Dana and JW Streilein
Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts 02114, USA.
PURPOSE: To delineate the time course for loss of immune privilege after induction of corneal neovascularization (NV), and to test whether treatment with angiostatic agents can restore the eye's capacity to induce anterior chamber-associated immune deviation (ACAID). METHODS: Corneal NV in murine eyes was induced by placement of intrastromal sutures. At different time points after NV induction, study eyes were initiated on a 10-day regimen of one of a variety of anti-inflammatory or angiostatic agents. After the completion of their treatment regimen, eyes were tested as to whether they could support ACAID. To test whether any observed effect on the delayed-type hypersensitivity response was because of a systemic absorption of the topically applied medication, certain animals had only their fellow eyes treated. RESULTS: Inflammatory corneal NV leads to the loss of immune privilege during the first week of the NV induction. Left untreated, these eyes remain incapable of supporting ACAID, even weeks after the initial corneal insult. However, when treatment with an anti-inflammatory agent is initiated during the first 2 weeks after the NV induction, these eyes show a restored capacity for ACAID induction, and this appears to be unrelated to any systemic effect of the treatment regimen. Treatment started at later time points is not capable of restoring the eye's normal capacity for inducing deviant immunity. CONCLUSIONS: Corneal neovascularization leads to loss of immune privilege in the anterior segment manifested as the inability to sustain ACAID. Moreover, topical angiostatic strategies can lead to restoration of immune privilege when instituted sufficiently early in the course of the neovascular response.
This article has been cited by other articles:
|
|
 |
|
  D. Hos, F. Bock, T. Dietrich, J. Onderka, F. E. Kruse, K.-H. Thierauch, and C. Cursiefen Inflammatory Corneal (Lymph)angiogenesis Is Blocked by VEGFR-Tyrosine Kinase Inhibitor ZK 261991, Resulting in Improved Graft Survival after Corneal Transplantation Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1836 - 1842. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Zagon, M. S. Klocek, J. W. Griffith, J. W. Sassani, A. M. Komaromy, and P. J. McLaughlin Prevention of Exuberant Granulation Tissue and Neovascularization in the Rat Cornea by Naltrexone Arch Ophthalmol, April 1, 2008; 126(4): 501 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lu, L. Li, K. Kuno, Y. Wu, T. Baba, Y.-y. Li, X. Zhang, and N. Mukaida Protective Roles of the Fractalkine/CX3CL1-CX3CR1 Interactions in Alkali-Induced Corneal Neovascularization through Enhanced Antiangiogenic Factor Expression J. Immunol., March 15, 2008; 180(6): 4283 - 4291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bock, J. Onderka, T. Dietrich, B. Bachmann, F. E. Kruse, M. Paschke, G. Zahn, and C. Cursiefen Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2545 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mohan Eyes wide s-flt: clearly, avascular fidelity is a vascular endothelial growth factor family affair Br. J. Ophthalmol., April 1, 2007; 91(4): 412 - 413. [Full Text] [PDF]
|
|
|
|
|
|
B. R. Mwaikambo, F. Sennlaub, H. Ong, S. Chemtob, and P. Hardy Activation of CD36 Inhibits and Induces Regression of Inflammatory Corneal Neovascularization. Invest. Ophthalmol. Vis. Sci., October 1, 2006; 47(10): 4356 - 4364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Chen, C. Cursiefen, S. Barabino, Q. Zhang, and M. R. Dana Novel Expression and Characterization of Lymphatic Vessel Endothelial Hyaluronate Receptor 1 (LYVE-1) by Conjunctival Cells Invest. Ophthalmol. Vis. Sci., December 1, 2005; 46(12): 4536 - 4540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cursiefen, S. Ikeda, P. M. Nishina, R. S. Smith, A. Ikeda, D. Jackson, J.-S. Mo, L. Chen, M. R. Dana, B. Pytowski, et al. Spontaneous Corneal Hem- and Lymphangiogenesis in Mice with Destrin-Mutation Depend on VEGFR3 Signaling Am. J. Pathol., May 1, 2005; 166(5): 1367 - 1377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Jie, Z Pan, Y Chen, Y Wei, W Zhang, Y Wu, H Peng, and L Xu Non-specific tolerance induced by staphylococcal enterotoxin B in treating high risk corneal transplantation in rats Br. J. Ophthalmol., March 1, 2005; 89(3): 364 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cursiefen, J. Cao, L. Chen, Y. Liu, K. Maruyama, D. Jackson, F. E. Kruse, S. J. Wiegand, M. R. Dana, and J. W. Streilein Inhibition of Hemangiogenesis and Lymphangiogenesis after Normal-Risk Corneal Transplantation by Neutralizing VEGF Promotes Graft Survival Invest. Ophthalmol. Vis. Sci., August 1, 2004; 45(8): 2666 - 2673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Dana Corneal Antigen-Presenting Cells: Diversity, Plasticity, and Disguise The Cogan Lecture Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 722 - 727. [Full Text] [PDF]
|
|
|
|
|
|
S. Yamagami, S. Yokoo, T. Mimura, and S. Amano Effects of TGF-{beta}2 on Immune Response-Related Gene Expression Profiles in the Human Corneal Endothelium Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 515 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Cursiefen, U. Schlotzer-Schrehardt, M. Kuchle, L. Sorokin, S. Breiteneder-Geleff, K. Alitalo, and D. Jackson Lymphatic Vessels in Vascularized Human Corneas: Immunohistochemical Investigation Using LYVE-1 and Podoplanin Invest. Ophthalmol. Vis. Sci., July 1, 2002; 43(7): 2127 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, P. Hamrah, Q. Zhang, A. W. Taylor, and M. R. Dana Draining Lymph Nodes of Corneal Transplant Hosts Exhibit Evidence for Donor Major Histocompatibility Complex (MHC) Class II-positive Dendritic Cells Derived from MHC Class II-negative Grafts J. Exp. Med., January 22, 2002; 195(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y F Yang, M Matheson, J K G Dart, and I A Cree Persistence of acanthamoeba antigen following acanthamoeba keratitis Br. J. Ophthalmol., March 1, 2001; 85(3): 277 - 280. [Abstract] [Full Text]
|
|
|
|
|
|
J. Yamada, B. R. Ksander, and J. W. Streilein Cytotoxic T Cells Play No Essential Role in Acute Rejection of Orthotopic Corneal Allografts in Mice Invest. Ophthalmol. Vis. Sci., February 1, 2001; 42(2): 386 - 392. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
